Halton joins RF’s 30-strong healthcare team as client services director after three years at SHI. She will work alongside existing client services director Penny Whitecross.
At SHI, Halton promoted brands such as AstraZeneca’s controversial cholesterol buster Crestor and Pfizer/Boehringer Ingelheim’s chronic obstructive pulmonary disease (COPD) product Spiriva. She also worked on various disease awareness campaigns in respiratory health.
Pinnington joins RF as an associate director from Lilly UK, where she worked for more than three years. At Lilly, she promoted the launches of osteoporosis brand Forsteo, Yentreve for stress urinary incontinence and antidepressant Cymbalta. She also worked on Lilly’s diabetes portfolio.
At RF, Pinnington is directing the Novartis cancer portfolio in the UK and the European programme for Schering’s Betaferon in multiple sclerosis.
The pair report to healthcare head and agency deputy MD Pat Pearson.